重组人血管内皮抑制素联合DC方案治疗晚期非小细胞肺癌的临床效果  

Clinical effect of recombinant human endostatin combined with DC regimen in the treatment of advanced non-small cell lung cancer

作　　者：谢传华 王志强 郭守俊 

机构地区：[1]江西省赣州市肿瘤医院化疗一科,江西赣州341000

出　　处：《中国当代医药》2015年第29期61-63,66,共4页China Modern Medicine

摘　　要：目的：探讨重组人血管内皮抑制素联合DC方案治疗晚期非小细胞肺癌（NSCLC）的效果。方法选取2013年1～7月本院收治的76例晚期NSCLC患者作为研究对象，根据随机数字表法将其分为A组（37例）和B组（39例）。B组给予DC方案治疗，A组在B组的基础上加用重组人血管内皮抑制素治疗，观察两组的有效率、疾病进展时间（TTP）、中位OS、1年生存率及化疗不良反应发生情况。结果 A组的有效率及临床获益率显著高于B组，差异有统计学意义（P〈0.05）。 A组的白细胞降低发生率显著低于B组，差异有统计学意义（P〈0.05）。A组的TTP显著长于B组，差异有统计学意义（P〈0.01）。A组的中位OS长于B组，差异有统计学意义（P〈0.05）。A组的1年生存率高于B组，差异有统计学意义（P〈0.05）。结论重组人血管内皮抑制素联合DC方案治疗晚期NSCLC疗效确切，能延长患者的存活时间，不良反应少，值得临床推广应用。Objective To explore the clinical effect of recombinant human endostatin combined with DC regimen in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods 76 patients with advanced NSCLC from January 2013 to July in our hospital were selected and divided into group A （37 cases） and group B （39 cases） according to the random number table method.Group B was given DC regimen,group A was given recombinant human endostatin on the basis of the group B.The effective rate,time to progress （TTP）,the median overall survival （OS）,one-year survival rate and adverse reaction due to chemotherapy was observed in two groups. Results The effective rate and the clinical benefit rate in group A was higher than that in group B,with significant difference （P〈0.05）.The incidence rate of white blood cell count decrease in group A was lower than that in group B,with significant difference （P〈0.05）.The TTP in group A was longer than that in group B,with significant difference （P〈0.01）.The median OS in group A was longer than that in group B,with significant difference （P〈0.05）.The one-year survival rate in group A was higher than that in group B,with significant difference （P〈0.05）. Conclusion Recombinant human endostatin combined with docetaxel in the treatment of patients with advanced NSCLC can obtain a definite effect,which can prolong patient’s survival time and less adverse reaction,it is worthy of promotion and application.

关 键 词：重组人血管内皮抑制素 晚期非小细胞肺癌 临床效果 

分 类 号：R734.2[医药卫生—肿瘤]